Effect of Propofol-Dexmedetomidine in Anesthesia Induction in Patients with Major Depression or Bipolar-Disorder under Electroconvulsive therapy

Comparing the Effect of Propofol-Dexmedetomidine versus Propofol in Anesthesia Induction in Patients with Major Depression or Bipolar-Disorder under Electroconvulsive therapy

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20231009059668N1

Enrollment

Registered

2023-10-22

Start date

2023-10-23

Completion date

Unknown

Last updated

2023-11-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Condition 1: Bipolar disorders. Condition 2: Major depression. Bipolar disorder Major depressive disorder, recurrent

Interventions

Intervention 1: Intervention group: Administration of propofol at a dose of 1 mg/kg along with receiving 0.5 µg/kg of dexmedetomidine to induce anesthesia. Intervention 2: Intervention group: administ

Eligibility

Sex/Gender

All

Age

18 Years to 50 Years

Inclusion criteria

Inclusion criteria: Age 18 to 50 years Patient in class 1 or 2 ASA physical status Patient diagnosed with major depression or bipolar disorder referred by a psychiatrist

Exclusion criteria

Exclusion criteria: History of cardiovascular, kidney, liver and lung disease History of other mental diseases, except major depression or bipolar disorder History of head trauma History of cardiovascular surgery History of allergy to propofol or foods such as eggs or soybeans Patient under treatment with bupropion and anticonvulsant The attending physician's lack of consent for the patient's participation in the study

Design outcomes

Primary

Measure	Time frame
Seizure duration. Timepoint: The end of the discharge time of the electric shock until the completion of all visible movements in all parts of the body. Method of measurement: Timer (seconds).;Recovery time. Timepoint: From the end of the injection of succinylcholine to the return of breathing and opening the eyes and following the instructions completely correctly by the patients. Method of measurement: Timer (minutes).;Hemodynamic changes (mean arterial pressure, heart rate). Timepoint: Before induction of anesthesia, during discharge of electric shock, 5, 10 and 15 minutes after discharge of electric shock. Method of measurement: Using a portable automatic monitoring (mean arterial pressure in mmHg and heart rate in beats per minute).	—

Measure

Time frame

Seizure duration. Timepoint: The end of the discharge time of the electric shock until the completion of all visible movements in all parts of the body. Method of measurement: Timer (seconds).;Recovery time. Timepoint: From the end of the injection of succinylcholine to the return of breathing and opening the eyes and following the instructions completely correctly by the patients. Method of measurement: Timer (minutes).;Hemodynamic changes (mean arterial pressure, heart rate). Timepoint: Before induction of anesthesia, during discharge of electric shock, 5, 10 and 15 minutes after discharge of electric shock. Method of measurement: Using a portable automatic monitoring (mean arterial pressure in mmHg and heart rate in beats per minute).

—

Secondary

Measure	Time frame
Pain. Timepoint: In 5, 10 and 15 minutes after the end of the electric shock discharge and also the recovery time. Method of measurement: Visual Analogue Scale.;Sedation and agitation. Timepoint: In 5, 10 and 15 minutes after the end of the electric shock discharge and also the recovery time. Method of measurement: Sedation-Agitation Scale.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactNegin Ghadami

Sanandaj University of Medical Sciences

ghadaminegin@gmail.com+98 87 3362 7228

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026